# A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

> **NCT01578499** · PHASE3 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 131 (actual)

## Conditions studied

- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Mycosis Fungoides
- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Methotrexate
- **DRUG:** Bexarotene

## Key facts

- **NCT ID:** NCT01578499
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-11
- **Primary completion:** 2016-05-31
- **Final completion:** 2018-07-06
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2021-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578499, "A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01578499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*